Nurix Therapeutics, Inc. (NRIX) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Nurix Therapeutics, Inc. (NRIX) Bundle
Simplify Nurix Therapeutics, Inc. (NRIX) valuation with this customizable DCF Calculator! Featuring real Nurix Therapeutics, Inc. (NRIX) financials and adjustable forecast inputs, you can test scenarios and uncover Nurix Therapeutics, Inc. (NRIX) fair value in minutes.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.1 | 17.8 | 29.8 | 38.6 | 77.0 | 106.5 | 147.3 | 203.8 | 282.0 | 390.1 |
| Revenue Growth, % | 0 | -42.73 | 66.95 | 29.84 | 99.31 | 38.34 | 38.34 | 38.34 | 38.34 | 38.34 |
| EBITDA | -19.9 | -62.8 | -111.8 | -173.1 | -141.4 | -98.8 | -136.7 | -189.1 | -261.6 | -361.9 |
| EBITDA, % | -63.9 | -352.43 | -375.81 | -448.03 | -183.68 | -92.78 | -92.78 | -92.78 | -92.78 | -92.78 |
| Depreciation | 2.4 | 2.2 | 6.1 | 10.8 | 13.7 | 18.3 | 25.3 | 35.0 | 48.5 | 67.1 |
| Depreciation, % | 7.57 | 12.23 | 20.44 | 27.98 | 17.74 | 17.19 | 17.19 | 17.19 | 17.19 | 17.19 |
| EBIT | -22.2 | -65.0 | -117.9 | -183.9 | -155.1 | -100.4 | -138.9 | -192.2 | -265.9 | -367.8 |
| EBIT, % | -71.46 | -364.66 | -396.26 | -476.01 | -201.41 | -94.29 | -94.29 | -94.29 | -94.29 | -94.29 |
| Total Cash | 37.7 | 281.1 | 295.7 | 309.1 | 287.9 | 106.5 | 147.3 | 203.8 | 282.0 | 390.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | 11.3 | 6.2 | .0 | .0 | 18.0 | 24.9 | 34.5 | 47.7 | 65.9 |
| Account Receivables, % | 0 | 63.67 | 20.85 | 0 | 0 | 16.9 | 16.9 | 16.9 | 16.9 | 16.9 |
| Inventories | .0 | .0 | .0 | -1.1 | .0 | -.6 | -.8 | -1.2 | -1.6 | -2.2 |
| Inventories, % | 0 | 0 | 0.000003361345 | -2.85 | 0 | -0.56955 | -0.56955 | -0.56955 | -0.56955 | -0.56955 |
| Accounts Payable | 1.6 | 3.4 | 6.7 | 5.1 | 6.4 | 14.5 | 20.1 | 27.7 | 38.4 | 53.1 |
| Accounts Payable, % | 5.14 | 19.15 | 22.35 | 13.11 | 8.31 | 13.61 | 13.61 | 13.61 | 13.61 | 13.61 |
| Capital Expenditure | -1.7 | -4.6 | -5.7 | -12.2 | -8.4 | -19.7 | -27.3 | -37.7 | -52.2 | -72.2 |
| Capital Expenditure, % | -5.31 | -25.55 | -19.03 | -31.7 | -10.91 | -18.5 | -18.5 | -18.5 | -18.5 | -18.5 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -22.5 | -44.1 | -118.0 | -169.3 | -155.1 | -92.4 | -127.8 | -176.8 | -244.5 | -338.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -20.2 | -56.0 | -109.2 | -165.0 | -149.6 | -103.1 | -130.8 | -181.0 | -250.4 | -346.4 |
| WACC, % | 14.54 | 14.5 | 14.54 | 14.53 | 14.54 | 14.53 | 14.53 | 14.53 | 14.53 | 14.53 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -631.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -353 | |||||||||
| Terminal Value | -2,820 | |||||||||
| Present Terminal Value | -1,431 | |||||||||
| Enterprise Value | -2,063 | |||||||||
| Net Debt | -24 | |||||||||
| Equity Value | -2,039 | |||||||||
| Diluted Shares Outstanding, MM | 54 | |||||||||
| Equity Value Per Share | -37.52 |
What You Will Get
- Comprehensive NRIX Financials: Access to both historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Evaluate various scenarios to assess Nurix Therapeutics' future performance.
- User-Friendly Interface: Designed for experts while remaining approachable for newcomers.
Key Features
- Comprehensive Financial Data: Access precise pre-loaded historical performance and future forecasts for Nurix Therapeutics, Inc. (NRIX).
- Adjustable Projection Parameters: Modify highlighted cells for key metrics such as WACC, growth rates, and profit margins.
- Real-Time Calculations: Instant updates to DCF, Net Present Value (NPV), and cash flow assessments.
- Interactive Visualization Tools: User-friendly charts and summaries to illustrate your valuation findings.
- Designed for All Levels: An intuitive layout suitable for investors, CFOs, and consultants alike.
How It Works
- Download the Template: Gain immediate access to the Excel-based NRIX DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and more.
- Instant Calculations: The model automatically recalculates Nurix Therapeutics’ intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential valuation changes.
- Analyze and Decide: Utilize the results to inform your investment or financial analysis.
Why Choose This Calculator for Nurix Therapeutics, Inc. (NRIX)?
- Accurate Data: Utilize real Nurix Therapeutics financials for trustworthy valuation outcomes.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations streamline the process, saving you from starting from scratch.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Featuring an intuitive design and clear step-by-step guidance for users of all experience levels.
Who Should Use This Product?
- Biotech Students: Understand drug development processes and apply them using real-world examples.
- Researchers: Integrate advanced therapeutic models into studies or publications.
- Investors: Evaluate your own hypotheses and assess valuation scenarios for Nurix Therapeutics, Inc. (NRIX).
- Analysts: Enhance your analysis with a comprehensive, customizable financial model.
- Pharmaceutical Entrepreneurs: Discover how major biotech firms like Nurix Therapeutics are evaluated.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Nurix Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Nurix Therapeutics, Inc. (NRIX).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.